The recombinant protein vaccine developed by HIPRA will start the clinical trial phase in June and will begin to be produced in October 2021
The president of the Government of Spain, Pedro Sanchez, visited the facilities of the multinational pharmaceutical company this Friday
The president of the Government of Spain, Pedro Sanchez, has visited the facilities of HIPRA's headquarters in Amer (Girona), a company that specializes in the research, production and marketing of vaccines, and with widespread experience in coronavirus. He was accompanied by the Minister of Health, Carolina Dario, and the Minister of Science and Innovation, Pedro Duque. Alba Vergés, the health secretary of the Generalitat of Catalonia, also attended, among other authorities. During the visit, the prime minister met with the Company's Management to follow at first hand the advances in research into the Covid-19 vaccine, whose clinical trials are expected to begin in June.
The vaccine, HIPRA SARS-CoV-2, is a recombinant protein vaccine that has been designed to optimize its safety and induce a potent immune response that neutralizes the Covid-19 virus. It will be kept between 2 and 8º C, which will facilitate its logistics and distribution. The vaccination strategy covers the various vaccination scenarios, effectiveness against different variants and the most likely and increasingly necessary booster doses.
Clinical trials are expected to conclude successfully, so that production can begin in October of this same year, with the aim of launching commercialization in late 2021, subject to obtaining the appropriate authorizations. According to current HIPRA projections, 400 million doses are expected to be produced during 2022. By 2023, 1.2 billion doses could be reached.
HIPRA, with 50 years of experience in vaccine development, has a unique organizational model, which internally controls all processes in the value chain, generating unique know-how and making it a benchmark in vaccine research, production and marketing.
The HIPRA project is supported by the Spanish Agency of Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS), as well as the Ministries of Health, Industry and Science and Innovation.
HIPRA is currently also conducting a line of research in collaboration with Hospital Clinic in Barcelona for the development of a Covid-19 vaccine based on the mRNA of the virus.
About HIPRA
HIPRA lies in 6th place in the worldwide ranking of animal health vaccines, and it is the laboratory that has launched the most innovative vaccines and technologies in the last ten years, with a total of 22 vaccines. The company closed the 2020 financial year with consolidated sales of 319 million Euros. In 2021, it expects 13.5% growth over the previous financial year. Currently, HIPRA has more than 2,000 people on its staff.
The company allocates 10% of its annual revenue to the research and development of new vaccines. It currently has 39 subsidiaries and 11 diagnostic centres worldwide and markets its products in more than 100 countries.
Since 2019, the company has been driving forward the HIPRA Campus project in Aiguaviva, which includes the expansion of its current facilities in a new complex that will accommodate various production and research units, as well as new business areas of the company, in an area of 114,000 m2. The project envisages an investment plan of €472 million up to 2026 and the direct creation of 580 highly qualified jobs.
HIPRA firmly believes that prevention is the key to the future both in animal health and human health, two sectors that must work hand-in-hand to combat various animal health challenges such as the COVID-19 pandemic.